Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 567 of 5804
-
New hope for blood disorder patients: experimental drug bomedemstat enters final trial phase
Disease control OngoingThis is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo shrinks untouchable liver tumors, opens door to surgery
Disease control OngoingThis is an open-label, single-arm, phase 2 study evaluating hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and cadonilimab as conversion therapy for initially unresectable hepatocellular carcinoma (HCC). The primary objective is to assess the conversion ra…
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New chemo cocktail aims to shrink hard-to-treat childhood muscle cancer
Disease control Recruiting nowThis multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of relapsed and refrac…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough leukemia: experimental drug AZD0486 enters human trials
Disease control Recruiting nowThis is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The stu…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for tough lymphomas: experimental drug targets cancer protein
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-l…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New triple therapy hopes to tame tough breast cancer
Disease control Recruiting nowThe purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for kids with Hard-to-Treat blood disorder
Disease control Recruiting nowTo evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TP…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New combo therapy targets hard-to-treat endometrial cancer
Disease control Recruiting nowA Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Phase: PHASE2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New inhaled drug shows promise for rare lung disease
Disease control CompletedThe primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot could tame rare metabolic disease
Disease control Recruiting nowThe purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care. Study details include: * Total Study duration: up to 38 weeks * Screening: * Initial Screening duration:…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Heart zapping vs. pills: which works better for stubborn irregular heartbeat?
Disease control OngoingThe purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.
Phase: NA • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refers to cells that have traits of both horm…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for progressive MS: drug aims to halt worsening disability
Disease control OngoingThe purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male an…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could vitamin c save lives after cardiac arrest? new trial investigates
Disease control Recruiting nowAmong patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting i…
Phase: PHASE2 • Sponsor: Centre Hospitalier de Bethune • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo aims to fight Drug-Resistant prostate cancer
Disease control Recruiting nowThis is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is…
Phase: PHASE2 • Sponsor: Edwin Posadas, MD • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill shows promise for rare lung cancer mutations
Disease control Recruiting nowThe main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Phase: PHASE2 • Sponsor: Teligene US • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gut radiation may revive immunotherapy in resistant cancers
Disease control CompletedPreclinical and clinical studies have shown that intestinal low dose radiotherapy (ILDR) can enhance antitumor immunity and response to immune checkpoint blockade (ICB). Therefore, the investigators launch a phase Ⅱ trial to evaluate the clinical value of combining ILDR and progr…
Phase: PHASE2 • Sponsor: Chuangzhen Chen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Placental clues from a past pregnancy may guide treatment to prevent future complications
Disease control Recruiting nowThe goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide …
Phase: PHASE2 • Sponsor: Endeavor Health • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could stem cells be the key to saving lives from Sepsis-Induced lung failure?
Disease control Recruiting nowThis study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients. The study is a randomized control trial - double blind, which has 3 arms intervention namely, Control treatment, UC-MSC treatment, and UC-MSC a…
Phase: PHASE1, PHASE2 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Radiation zaps resistant cancer spots, may extend immunotherapy success
Disease control Recruiting nowThis Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 mo…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC